Stockscreener 앱 받기
2.23%
시간 외 거래:
전일 마감가:
$25.60
열려 있는:
$25.79
하루 거래량:
45.19M
Relative Volume:
1.24
시가총액:
$149.15B
수익:
$63.32B
순이익/손실:
$7.52B
주가수익비율:
20.06
EPS:
1.3043
순현금흐름:
$9.48B
1주 성능:
+1.87%
1개월 성능:
+1.39%
6개월 성능:
+1.43%
1년 성능:
+6.90%
1일 변동 폭
$25.79
$26.48
1주일 범위
$25.47
$26.48
52주 변동 폭
$23.11
$28.75
화이자 Stock (PFE) Company Profile
명칭
Pfizer Inc
전화
(212) 733-2323
주소
66 HUDSON BOULEVARD EAST, NEW YORK, NY
Compare PFE vs LLY, JNJ, ABBV, MRK, NVS
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PFE
Pfizer Inc
|
26.17 | 145.91B | 63.32B | 7.52B | 9.48B | 1.3043 |
LLY
Lilly Eli Co
|
1,160.95 | 1.01T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
238.33 | 574.10B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
224.77 | 397.44B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
120.76 | 294.13B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
153.92 | 282.63B | 54.66B | 13.58B | 16.05B | 7.0171 |
화이자 Stock (PFE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-02 | 업그레이드 | Argus | Hold → Buy |
| 2026-02-25 | 개시 | RBC Capital Mkts | Underperform |
| 2026-02-20 | 개시 | Barclays | Underweight |
| 2026-02-12 | 다운그레이드 | Daiwa Securities | Outperform → Neutral |
| 2026-01-07 | 재개 | UBS | Neutral |
| 2025-12-02 | 재개 | Citigroup | Neutral |
| 2025-11-13 | 개시 | Scotiabank | Sector Outperform |
| 2025-04-22 | 개시 | Cantor Fitzgerald | Neutral |
| 2024-12-10 | 재개 | BofA Securities | Neutral |
| 2024-11-15 | 개시 | Wolfe Research | Underperform |
| 2024-10-25 | 재개 | Citigroup | Neutral |
| 2024-10-17 | 개시 | Bernstein | Mkt Perform |
| 2024-08-07 | 업그레이드 | Daiwa Securities | Neutral → Outperform |
| 2024-03-22 | 다운그레이드 | Argus | Buy → Hold |
| 2024-02-23 | 개시 | Guggenheim | Buy |
| 2024-01-04 | 다운그레이드 | TD Cowen | Outperform → Market Perform |
| 2023-10-20 | 재개 | UBS | Neutral |
| 2023-10-16 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-07-17 | 재확인 | JP Morgan | Neutral |
| 2023-07-14 | 개시 | HSBC Securities | Buy |
| 2023-06-29 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2023-05-11 | 다운그레이드 | Daiwa Securities | Outperform → Neutral |
| 2023-03-06 | 개시 | Jefferies | Hold |
| 2023-02-07 | 업그레이드 | Daiwa Securities | Neutral → Outperform |
| 2023-01-26 | 다운그레이드 | UBS | Buy → Neutral |
| 2023-01-17 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2023-01-04 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2022-12-13 | 업그레이드 | Goldman | Neutral → Buy |
| 2022-11-18 | 개시 | Credit Suisse | Outperform |
| 2022-05-23 | 개시 | SVB Leerink | Mkt Perform |
| 2022-04-06 | 재개 | Morgan Stanley | Equal-Weight |
| 2022-01-05 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2022-01-03 | 재확인 | Bernstein | Mkt Perform |
| 2021-12-20 | 재확인 | Cowen | Outperform |
| 2021-12-17 | 개시 | Goldman | Neutral |
| 2021-12-13 | 업그레이드 | UBS | Neutral → Buy |
| 2021-12-09 | 개시 | Wells Fargo | Overweight |
| 2021-11-19 | 개시 | BMO Capital Markets | Outperform |
| 2021-07-27 | 재개 | Truist | Buy |
| 2021-05-06 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2021-04-07 | 재개 | RBC Capital Mkts | Sector Perform |
| 2021-02-04 | 업그레이드 | DZ Bank | Hold → Buy |
| 2020-12-16 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-11-19 | 재개 | Goldman | Neutral |
| 2020-11-10 | 재개 | Bernstein | Mkt Perform |
| 2020-10-12 | 다운그레이드 | Atlantic Equities | Overweight → Neutral |
| 2020-09-29 | 개시 | Berenberg | Hold |
| 2020-06-16 | 개시 | SVB Leerink | Mkt Perform |
| 2020-02-27 | 개시 | Barclays | Equal Weight |
| 2020-02-27 | 업그레이드 | Standpoint Research | Hold → Buy |
| 2020-02-06 | 개시 | Mizuho | Buy |
| 2020-01-07 | 개시 | RBC Capital Mkts | Outperform |
| 2019-10-17 | 재개 | BofA/Merrill | Neutral |
| 2019-07-30 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2019-07-30 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2019-06-04 | 재개 | Morgan Stanley | Overweight |
| 2019-02-20 | 재개 | Citigroup | Neutral |
| 2019-01-31 | 업그레이드 | Argus | Hold → Buy |
| 2019-01-31 | 업그레이드 | Credit Suisse | Neutral → Outperform |
| 2019-01-23 | 다운그레이드 | UBS | Buy → Neutral |
| 2018-12-11 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2018-11-01 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
모두보기
화이자 주식(PFE)의 최신 뉴스
Pfizer (PFE) Outpaces Stock Market Gains: What You Should Know - Yahoo Finance
Pfizer (NYSE:PFE) Shares Up 2.2%Here's What Happened - MarketBeat
This $25 Billion Acquisition Just Unlocked a New Era of Growth for Pfizer — and Why It’s a Flawless Safe-Haven for Retirees - Yahoo Finance
Bristol Myers Squibb Dividend Raise Streak is 18 Years. Here's 1 Number That Says the Streak Will Continue. - The Motley Fool
Pfizer’s New Phase 1 PF-07799544 Study Adds Quiet Depth to Its R&D Pipeline - TipRanks
Why Pfizer Stock Popped Today - The Globe and Mail
Pfizer Shares Edge Higher on RBC Upgrade, German Pricing Risk in Focus - TechStock²
Lexicon Pharmaceuticals vs Pfizer: Comparing a Small Biotech with a Global DrugmakerNews and Statistics - IndexBox
Pfizer shares climb 3.2% as investors digest expanded U.S. label for HYMPAVZI - Quiver Quantitative
Lexicon Pharmaceuticals vs. Pfizer: Which Drugmaker Stock Is a Better Buy in 2026? - Yahoo Finance
Pfizer Inc. $PFE Stock Position Lowered by Townsquare Capital LLC - MarketBeat
Insider Sell: Jennifer Damico Sells 2,000 Shares of Pfizer Inc (PFE) - GuruFocus
Veteran Analyst Revamps Pfizer Stock Price Target for Rest of 2026 - TradingView
Roche and Pfizer race to lead obesity and diabetes drug market with promising new treatments. - Pluang
Roche Vs. Pfizer: Obesity Week Presentations Deep DiveWhat Investors Must Know (RHHBY) - Seeking Alpha
Pfizer Steps Up in Obesity Race With New Mid-Stage SOLIS-1 Trial - TipRanks
Pfizer pulls out of summit with Germany's Merz over health care reform - Yahoo Finance
Pfizer CEO warns German investment at risk over drug pricing policies - Reuters
Pfizer's 2025 Impact Report Highlights Progress Across Patients, Planet, and Responsible Business - Pfizer
Pfizer Stock 2026: CEO Lays Out the Case for a Growth Surge - TIKR.com
Pfizer upgraded at RBC Capital Markets on risk-reward setup - MSN
Pfizer stock upgraded at RBC Capital Markets (PFE:NYSE) - Seeking Alpha
Wills Financial Group LLC Increases Stake in Pfizer Inc. $PFE - MarketBeat
Letko Brosseau & Associates Inc. Sells 160,000 Shares of Pfizer Inc. $PFE - MarketBeat
RBC Upgrades Pfizer to Sector Perform from Underperform, PT is $25 - marketscreener.com
Deutsche Bank AG Has $769.38 Million Stock Holdings in Pfizer Inc. $PFE - MarketBeat
FDA Approval for HYMPAVZI issued to PFIZER INC - Quantisnow
Cerity Partners LLC Buys 1,448,806 Shares of Pfizer Inc. $PFE - MarketBeat
RBC Capital upgrades Pfizer stock rating on valuation - Investing.com
RBC Capital upgrades Pfizer stock rating on valuation By Investing.com - Investing.com Canada
Prediction: Pfizer Stock Will Double on This Date - 24/7 Wall St.
Pfizer’s HYMPAVZI Pediatric Approval Deepens Rare Disease Growth Story - Yahoo Finance UK
Pfizer & Merck Rebuild Growth After Pandemic Revenue Shift - Kalkine Media
Amneal and Pfizer GLP-1 Deal: New Growth Lever? - Yahoo Finance
Analysts Offer Insights on Healthcare Companies: Cullinan Management (CGEM), Pfizer (PFE) and Novo Nordisk (NVO) - The Globe and Mail
Will obesity drugs save Pfizer from its post-COVID slump? - Pharma Voice
Daily short sale tracking: Pfizer's short volume increased by 4 million, with a short sale ratio of 19% - Moomoo
Pfizer Falls in Premarket; Fresh FDA Approval Not Lifting the Stock - TechStock²
BMO Capital Sticks to Their Buy Rating for Pfizer (PFE) - The Globe and Mail
Analysts Have Conflicting Sentiments on These Healthcare Companies: Entrada Therapeutics Inc (TRDA) and Pfizer (PFE) - The Globe and Mail
Pfizer, Zai Lab win China nod for cervical cancer therapy Tivdak - Seeking Alpha
Pfizer, Inc. (PFE) Stock Analysis: Exploring a 12% Potential Upside Amid Robust Free Cash Flow and Strong Dividend Yield - DirectorsTalk Interviews
CenterBook Partners LP Lowers Position in Pfizer Inc. $PFE - MarketBeat
Pfizer's Hympavzi Approved for Pediatric Hemophilia Treatment - GuruFocus
US FDA approves Pfizer's bleeding disorder drug for children - Reuters
Comirnaty COVID-19 vaccine: how Pfizer’s mRNA shot fits today - AD HOC NEWS
Pfizer Options Spot-On: On June 8th, 235.27K Contracts Were Traded, With 2.71 Million Open Interest - Moomoo
Pfizer Inc. stock (US7170811035): FDA expands hemophilia drug label as investors eye pipeline beyond - AD HOC NEWS
Pfizer's Obesity Drug Shows 16% Weight Loss In Phase 2b Study - Benzinga
Pfizer’s Hympavzi Gets FDA Approval for Expanded Indication - Contract Pharma
Transcript : Pfizer Inc. Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026, Jun-08-2026 08 - marketscreener.com
화이자 (PFE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.61%
자본화:
|
볼륨(24시간):